How India Exports Carboplatin to the World

In the United States, carboplatin is approved under multiple Abbreviated New Drug Applications (ANDAs), as listed in the FDA's Orange Book. The regulatory pathway for carboplatin involves demonstrating bioequivalence to the reference listed drug, facilitating the approval of generic versions. Given the presence of 273 active Indian exporters and 829 buyers, with a repeat buyer rate of 63.6%, the US market remains a critical destination for Indian carboplatin exports.

In the European Union, carboplatin is subject to marketing authorization by the European Medicines Agency (EMA). The EMA has conducted periodic safety update report single assessments (PSUSAs) for carboplatin, with the most recent assessment completed in November 2022. These assessments ensure the continued safety and efficacy of the drug within the EU market. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting to the EU, ensuring product quality and safety.

Carboplatin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The drug is also subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, carboplatin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) sets ceiling prices for essential medicines; however, specific ceiling prices for carboplatin should be verified with the latest NPPA notifications. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of carboplatin, ensuring compliance with national regulations.

Carboplatin's primary patents have expired, leading to a competitive generic market. This has facilitated the entry of multiple manufacturers, including Indian exporters, into global markets. The absence of active patents allows for increased accessibility and affordability of the drug worldwide.

In November 2022, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) completed a periodic safety update report single assessment (PSUSA) for carboplatin, resulting in variations to the terms of marketing authorizations to enhance patient safety. Additionally, in January 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Zynyz, recommending its use in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal. These developments reflect ongoing regulatory oversight and the evolving therapeutic applications of carboplatin in combination therapies.

Carboplatin, a critical chemotherapy agent, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a global leader in this sector. This dependency exposes the supply chain to significant risks, as any disruption in China's KSM production can directly impact Carboplatin API availability.

Recent events have underscored this vulnerability. In July 2018, environmental regulations led to the shutdown of several Chinese chemical plants, causing a ripple effect that disrupted global pharmaceutical supply chains. Indian pharmaceutical companies, heavily reliant on Chinese KSMs, faced increased costs and supply uncertainties. Such incidents highlight the fragility of the current sourcing model and the need for diversification to mitigate future risks.

Our proprietary trade data from 2022 to 2026 reveals a high concentration among Carboplatin exporters in India. The top five exporters account for 65.8% of total exports, with FRESENIUS KABI ONCOLOGY LIMITED alone contributing 38.8% ($27.5M USD). This concentration poses a significant single-source risk; any operational or regulatory issues affecting these key players could disrupt global supply chains.

To address such vulnerabilities, the Indian government introduced the Production Linked Incentive (PLI) scheme aimed at boosting domestic API and KSM production. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, marking a step towards reducing import dependence. However, as of March 2026, similar initiatives for Carboplatin's KSMs are yet to be realized, leaving the supply chain exposed to existing risks.

The global pharmaceutical supply chain is susceptible to geopolitical tensions and shipping disruptions. The Red Sea and Strait of Hormuz are critical maritime routes for raw material shipments; any instability in these regions can delay supplies. Additionally, escalating US-China trade tensions have led to tariffs and export restrictions, further complicating the procurement of Chinese-sourced KSMs.

These disruptions have tangible impacts. In August 2024, the European Medicines Agency (EMA) reported a shortage of Cisplatin, a chemotherapy drug similar to Carboplatin, due to manufacturing capacity issues in India. This shortage affected multiple EU member states and was expected to last until 2025. (ema.europa.eu) Such incidents underscore the interconnectedness of global supply chains and the cascading effects of regional disruptions.

• Diversify KSM Sourcing: Identify and develop alternative suppliers for Carboplatin's KSMs beyond China to reduce dependency and enhance supply chain resilience.

• Invest in Domestic Production: Leverage government incentives like the PLI scheme to establish domestic manufacturing facilities for critical KSMs and APIs.

• Enhance Supplier Audits: Implement rigorous quality and compliance audits for existing suppliers to preempt potential disruptions due to regulatory issues.

• Develop Contingency Plans: Establish strategic reserves and alternative logistics routes to mitigate the impact of geopolitical and shipping disruptions.

• Strengthen Regulatory Collaboration: Engage with international regulatory bodies to monitor and address potential shortages proactively, ensuring timely interventions.

RISK_LEVEL: HIGH